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AbstrAct
Recent developments have set the stage for immunotherapy as a supplement 
to conventional cancer treatment. Consequently, a significant effort is required to 
further improve efficacy and specificity, particularly the identification of optimal 
therapeutic targets for clinical testing. Cancer/testis antigens are immunogenic, 
highly cancer-specific, and frequently expressed in various types of cancer, which 
make them promising candidate targets for cancer immunotherapy, including cancer 
vaccination and adoptive T-cell transfer with chimeric T-cell receptors. Our current 
understanding of tumor immunology and immune escape suggests that targeting 
oncogenic antigens may be beneficial, meaning that identification of cancer/testis 
antigens with oncogenic properties is of high priority. Recent work from our lab and 
others provide evidence that many cancer/testis antigens, in fact, have oncogenic 
functions, including support of growth, survival and metastasis. This novel insight 
into the function of cancer/testis antigens has the potential to deliver more effective 
cancer vaccines. Moreover, immune targeting of oncogenic cancer/testis antigens in 
combination with conventional cytotoxic therapies or novel immunotherapies such as 
checkpoint blockade or adoptive transfer, represents a highly synergistic approach 
with the potential to improve patient survival.
INtrODUctION
It is clear that most cancers are immunogenic, and 
that the immune system can, under certain conditions, 
control tumor growth. However, it appears that in patients 
with evident disease, the spontaneous immune responses 
are unable to control tumor growth and, consequently, a 
significant research effort has been initiated to boost anti-
tumor immune responses by therapeutic interventions, e.g. 
antibodies targeting inhibitory T-cell pathways, cancer 
vaccines or the adoptive transfer of in vitro expanded T 
cells. Recently, recombinant or chimeric T-cell antigen 
receptors have been introduced for adoptive T-cell therapy, 
an approach wherein polyclonal T cells are redirected 
toward cancer cells that express defined antigens by 
the transfer of genes encoding those antigen-specific 
receptors.
T cells are the major effector cells involved in the 
immune surveillance of cancer by virtue of their ability to 
detect quantitative and qualitative differences of presented 
antigens on transformed cells. Indeed, carcinogenic 
alterations result in an altered protein repertoire. Among 
the different types of tumor antigens, cancer/testis (CT) 
antigens represent highly promising therapeutic targets 
due to a unique set of features. In healthy adults, CT 
antigen expression is limited to male germ cells, but 
ectopic expression can be observed in tumor cells of 
multiple types of human cancer [1-7]. Male germ cells 
are devoid of HLA-class I molecules and cannot present 
antigens to T cells [8]. Therefore, CT antigens can be 
considered neoantigens when expressed in cancer cells 
and have the capacity to elicit immune responses that 
are strictly cancer-specific. While the immune-privileged 
nature of testis germ cells will likely result in decrease or 
absence of peripheral immune tolerance to CT antigens 
[9], CT antigen expression has been demonstrated in the 
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medullary thymic epithelial cells that mediate negative 
selection of self-reactive T cells to tissue-specific proteins 
[10]. Nonetheless, cellular and humoral immune responses 
to CT antigens are frequently observed in cancer patients 
[11-18], and there is an association between CT antigen 
expression and cytolytic activity of tumor immune 
infiltrates [19]. Thus, CT antigens represent the promise 
of highly specific immune targeting of a wide range of 
human cancers. 
In a milestone article (as well as a sequel article 
a decade later), Hanahan and Weinberg described ‘the 
hallmarks of cancer’, i.e., the characteristic features of 
cancer cells, including the capacity for uncontrolled 
growth (abnormal cell cycle regulation), resistance to 
death (apoptosis resistance), the potential to migrate and 
grow at distant sites (metastasis), and the ability to induce 
the growth of new blood vessels (attract endothelial cells), 
etc [20, 21]. It is well established that molecular events 
(genetic and epigenetic changes) are responsible for these 
cancer traits. In Hanahan and Weinberg’s recent update, 
immune evasion by cancer cells was also included as a 
hallmark. Our current understanding of tumor immunology 
suggests that tumor antigen-negative variants may evolve 
as the result of immunologic pressure, and thus it would be 
beneficial to target antigens, which, if lost, would reduce 
the ability of the cancer cells to thrive [22]. Thus, the 
proteins or protein patterns associated with, or responsible 
for, these hallmarks of cancer represent ideal targets for 
therapeutic intervention, including immunotherapy. 
Several T-cell antigens involved with these cancer traits 
have been characterized, as exemplified by Cyp1B1, 
telomerase, survivin (cell division), Bcl-2, Bcl-X(L), 
survivin, (resistance to apoptosis), RhoC (metastatic 
potential), survivin, VEGFR (angiogenesis). However, 
none of them exhibit the cancer-specific expression of CT 
antigens. Thus, the identification of oncogenic CT antigens 
(onco-CTAs) is of high priority, but requires in-depth 
characterization of the molecular and cellular functions of 
CT antigens. Only recently have critical insights into the 
function CT antigens in tumor cells emerged that, indeed, 
suggest the oncogenic functions of multiple CT antigens. 
In this article, we review the current understanding 
of CT antigen functions in oncogenesis and discuss how 
this novel insight may result in more effective cancer 
vaccines and new therapeutic strategies.
tHE cANcEr/tEstIs ANtIGEN GrOUP
MAGE-1 (melanoma-associated antigen 1) was the 
first CT antigen to be discovered twenty years ago using 
autologous typing with T-cell clones from a melanoma 
patient with a favorable clinical course [23]. Further typing 
of cancer patient T cells and serological analysis of cDNA 
libraries (SEREX) subsequently lead to the identification 
of many additional immunogenic CT antigens [24-28]. In 
recent years, however, additional CT antigens have been 
added purely based on expression profiling in normal and 
malignant tissues, and therefore the antigenic properties 
of many of these remain elusive [29-32]. At present, 
the known CT antigen group consists of more than 200 
proteins [33], a number that is continuously increasing (an 
overview is provided in Supplementary Table 1 and 2, data 
from the CTDatabase at http://www.cta.lncc.br). 
CT antigens can be categorized into two subclasses 
depending on the chromosomal localization of their 
encoding genes. One subclass is the chromosome 
X-encoded CT antigens (Supplementary Table 1), which 
are generally highly germ cell-specific and immunogenic. 
Remarkably, CT antigens constitute more than 10% of the 
coding sequence on the X chromosome [34], and there 
appears to have been a strong diversifying selection of CT 
antigen genes during primate evolution resulting in the 
generation of CT antigen families with multiple members 
(MAGE, GAGE, SSX, CT45 etc.) [34, 35]. For instance, 
the MAGE CT antigens have evolved on three different 
clusters on chromosome X encoding the MAGE-A, -B 
and -C subfamilies with 12, 6 and 2 members, respectively 
[36]. All MAGE proteins contain the MAGE-homology 
domain, but otherwise exhibit significant differences in 
structure and function. In contrast to MAGE genes, the 
GAGE gene cluster is very heterogeneous, comprising 
from 13 to 39 gene copies encoding highly identical, 
and likely functionally similar, GAGE proteins [37-39]. 
Chromosome X-encoded CT antigens tend to be expressed 
during the fetal stages of germ cell development and in 
undifferentiated adult male germ cells (i.e. spermatogonia). 
The additional subclass of CT antigens is composed 
primarily of proteins encoded by single-copy genes 
located on the autosome (BAGE, HAGE, SP17 etc.; 
Supplementary Table 2). These CT antigens tend to be 
expressed in meiotic and post-meiotic stages of male germ 
cells and their expression frequency in cancer is generally 
lower [40]. 
Notably, not all CT antigens are strictly limited to 
male germ cells in normal tissues. Some can be further 
classified as testis-restricted (only testis), testis-selective 
(testis and no more than 2 additional tissues) or testis/
brain-restricted (expressed in testis and the central nervous 
system) [3]. How the expression of some CT antigens in a 
limited number of normal tissues other than testis affects 
their antigenic properties and potential as therapeutic 
targets remains largely unresolved. 
ONcOGENIc FUNctIONs OF cANcEr/
tEstIs ANtIGENs
Cells of the germ line and the closely related 
trophoblasts share many features with cancer cells 
(Figure 1). For instance, when primitive germ cells (i.e. 
primordial germ cells) arise in the wall of the yolk sac 
they are highly motile and able to penetrate tissues as they 
journey to the gonadal primordium [41]. This process 
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Figure 1: shared characteristics between germ cells and cancer cells. Germ cells and cancer cells share many features that are 
absent in most other cell types, suggesting that germ cell programs contribute to cancer development and progression. In addition to cancer/
testis antigen expression, these characteristics include proliferation, migration, colonization and meiosis/genomic instability. 
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of germ cell colonization of the gonad in many ways 
resembles the progression of cancer cells from primary 
tumor to metastasis. Moreover, during spermatogenesis, 
germ cells exhibit characteristics similar to cancer cells. 
The immature spermatogonia maintain their proliferative 
capacity throughout life and continuously differentiate into 
spermatocytes, which go through meiosis comparable to 
the chromosomal changes observed in most cancers. 
Trophoblasts also exhibit overlapping features with 
cancer cells, as they are invasive and burrow into the 
endometrium to implant the embryo, as well as proliferate 
vigorously to form the non-maternal part of the placenta. 
These observations led to the hypothesis that activation 
of embryonic or gametogenic programs are among the 
driving forces of tumorigenesis [42], a concept supported 
by the fact that many germ cell and placental proteins, 
including CT antigens, are aberrantly expressed in cancer 
[43, 44]. In recent years, the functions of CT antigens 
have received extensive investigation, and the emerging 
data are consistent with the concept that reactivation of 
germline genes might confer central characteristics to 
cancer cells (Figure 2). 
Multiple cancer/testis antigens affect cancer cell 
growth
Sustained growth is an important feature of all 
cancer cells and the net result of deregulation of the 
delicate cell cycle machinery that balances proliferative 
signaling and cell survival signals. Importantly, multiple 
CT antigens have been shown to support cancer cell 
growth. We have recently shown that knockdown of the 
CT antigen SSX2 in melanoma cancer cells significantly 
reduces cellular proliferation [45]. This finding was 
supported by another study demonstrating that SSX 
proteins activate several important growth pathways, 
such as MAPK and Wnt [46]. SSX2 is a DNA binding 
protein that associates with and regulates the structure of 
chromatin [47]. This includes, but is likely not limited to, 
antagonistic regulation of the function of Polycomb Group 
proteins, which are important epigenetic regulators of gene 
expression and implicated in cancer development [48]. 
Thus, current results suggest that SSX proteins support 
cancer cell proliferation through regulation of gene 
expression. The CAGE CT antigen also seems to promote 
Figure 2: Oncogenic functions of cancer/testis antigens. Tumorigenesis involves acquisition of a specific set of essential 
capabilities (as described in the ‘Hallmarks of cancer’ by Hanahan and Weinberg”[20, 21]). These include uncontrolled growth, resistance 
to death (apoptosis), the potential to migrate and grow at distant sites (invasion and metastasis), the ability to induce the growth of new 
blood vessels (induce angiogenesis), etc. Underlying these hallmarks is genomic instability, which generates the genetic variation that 
accelerates their acquisition. Cancer/testis antigens confer several of these important capabilities to cancer cells, suggesting that they are 
directly implicated in tumorigenesis.
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cell proliferation as it has been shown to enhance Cyclin 
D1 and E levels, thereby stimulating cell cycle progression 
[49]. Furthermore, CAGE have angiogenic potential, 
which may indirectly support cancer cell growth [50].
MAGE proteins are among the functionally and 
immunologically most well-characterized CT antigens, 
and several members of the MAGE CT antigen family 
have been implicated in cancer cell survival [51-60]. 
Most importantly, MAGE CT antigens bind and regulate 
the function of the essential tumor suppressor p53, 
thereby increasing survival of cancer cells. Knockdown 
of MAGE-A, -B and -C proteins in melanoma cells 
inhibited complexing of p53 and its co-repressor KAP1, 
leading to increased p53 activity and apoptosis [59]. 
Further, MAGE-A proteins have been demonstrated 
to directly block the interaction of p53 with chromatin, 
thereby inhibiting its effect as a transcriptional regulator 
[60], and to strongly down-regulate p53 function by 
recruiting transcription repressors [histone deacetylases 
(HDACs)] to p53-regulated genes [57]. In addition, 
multiple MAGE family proteins have been identified 
as functional regulators of E3 RING ubiquitin ligases, 
which facilitate the proteasomal degradation of many 
proteins, including p53 [58]. Members of the GAGE-
like CT antigen family (GAGE and PAGE proteins) also 
confer apoptotic resistance to various types of cancer 
cells. GAGE7 prevented apoptosis in response to different 
types of apoptotic stimuli [55, 61, 62], and knockdown of 
PAGE4 induced cell death and attenuated tumor growth 
in vivo [63]. 
Cellular senescence is a state of irreversible 
growth arrest that can occur, for example, in response 
to excessive oncogene stimulation, and seems to be an 
important tumor suppressor mechanism [64]. Currently, 
little is known about how cells bypass the senescence 
response in tumorigenesis, although a growing body of 
evidence implicates the involvement of Mage-A2. In 
human fibroblasts, Mage-A2 was found to maintain cell 
proliferation in response to RasV12 expression by limiting 
the senescence response to this oncogene [65]. This effect 
of Mage-A2 was also attributed to its inhibition of p53 
function, suggesting that MAGE-A2 could play a novel 
role in early progression to malignancy by interfering with 
p53 function. This may block the senescence program, a 
critical barrier against cell transformation. Further studies 
addressing the potential cooperation between CT antigens 
interfering with cell cycle regulation and oncogenic 
signaling should be of high priority. 
The above results show that several CT antigens 
may support tumor growth, but also indicate that CT 
antigens may be important in treatment responses to 
cytotoxic or growth inhibitory anti-cancer drugs. Clearly, 
all CT antigens that enhance cell survival may decrease 
the effectiveness of treatment with cytotoxic agents. This 
has been demonstrated with MAGE-A, MAGE-C, GAGE, 
PAGE-4 and CAGE, which render cells resistant to DNA 
damage-inducing drugs commonly used in the clinic, such 
as etoposide and paclitaxel [52, 55, 57, 61, 63, 66], as well 
as additional cytotoxic drugs used in cancer treatment [51, 
52, 61]. MAGE-A proteins have also been proposed to be 
involved in development of tamoxifen-resistance in breast 
cancer since they are up-regulated in tamoxifen-resistant 
clones and knockdown of MAGE-A2 sensitized cells 
to tamoxifen. Further, significant association between 
MAGE-A expression and reduced overall survival 
in a series of estrogen receptor-positive, tamoxifen-
treated, breast cancer patients was observed [67]. Thus 
CT antigens may be considered as both prognostic and 
predictive markers. 
cancer/testis antigens and metastasis formation
A clear link between CT antigen expression and 
cancer progression has been observed [7, 68-71]. CT 
antigens are rarely expressed in benign neoplastic lesions, 
such as carcinoma in situ and melanocytic nevi [72], but 
are frequently expressed in primary melanoma, and even 
more frequently in metastases. For example, the frequency 
of MAGE-A1 and -A4 expression in primary melanoma 
tumors were 20% and 9%, respectively, but 51% and 44%, 
respectively, in distant metastases [71]. This indicates that 
CT antigens may play a direct role in the highly complex 
process of metastasis, which involves several steps, 
including local invasion, intravasation into blood and 
lymphatic vessels, survival in the circulation, extravasation 
into distant tissues and colonization. An important 
feature of cells with metastatic capability is increased 
motility and invasive potential. Interestingly, several CT 
antigens, including MAGE-C2, GAGE, XAGE1, CAGE 
and CT45A1, have been demonstrated to enhance both 
phenotypes [73-75]. Epithelial-to-mesenchymal transition 
(EMT) is a process by which epithelial cells lose their 
cell-cell adhesion and cell polarity, and gain migratory 
and invasive properties characteristic of mesenchymal 
cells. EMT has been shown to be instrumental for 
metastatic progression of several types of cancer, 
especially melanoma [76]. Molecular analysis of the 
effects of MAGE-C2 expression in breast cancer cells 
revealed signs of EMT (i.e. reduced E-cadherin, reduced 
cytokeratin, increased vimentin and increased fibronectin) 
[73]. Similarly, SSX, CAGE and CT45A1 have been 
shown to regulate the function of central EMT proteins 
(i.e. beta-catenin, SNAIL and TWIST) [46, 74, 77], and 
may support the transition to a metastatic phenotype. 
In contrast to melanocyte differentiation antigens (i.e. 
MART and GP100), which are down-regulated during 
EMT, CT antigens have been shown to be up-regulated or 
unchanged in expression [78]. This is consistent with the 
enhanced expression of CT antigens in metastases relative 
to primary tumors, and suggests that CT antigens may be 
prime candidates for blocking metastatic progression or 
targeting cancer cells in established metastatic lesions. 
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GAGE proteins are the only CT antigens that have 
been identified in both migrating primordial germ cells and 
trophoectodermal cells [79, 80], which are highly motile 
and invasive. Furthermore, knockdown of GAGE proteins 
in melanoma cells lines greatly reduce their migration and 
invasion. We, and others, have found that GAGE proteins 
are highly up-regulated in metastatic clones of isogenic 
breast and gastric cancer models, further suggesting 
a role in metastasis formation [81]. However, direct 
involvement of GAGE proteins in metastasis remains to 
be demonstrated. Further elucidating the effect of GAGE 
proteins as well as additional CT antigens on metastases 
formation in in vivo models should be of high priority. 
cancer/testis antigens and genomic integrity
The genome of cancer cells is unstable and 
constantly subject to mutations, chromosomal 
rearrangements and loss or gain of chromosomes. This 
genomic instability is largely responsible for the generation 
of mutant genotypes that confer selective advantages on 
cell subclones that, in turn, supports tumorigenesis. The 
extent to which different mechanisms affect genomic 
instability is controversial, but DNA double-strand breaks 
and abnormal segregation of chromatids during mitosis are 
generally accepted to be involved. In addition, the meiotic 
process involves the generation of double-strand breaks 
during the exchange of genetic material between sister 
chromatids and pairing and segregation of chromatids. 
Therefore, it can be speculated that activation of meiotic 
programs in cancer cells may contribute to genome 
instability, and that meiosis-specific CT antigens, such as 
SPO11, SCP1 and HORMAD1, may be involved [31, 82, 
83]. SPO11 is instrumental to meiotic chromatid exchange 
of genetic material by producing double strand breaks [84] 
and might promote chromosomal rearrangements in cancer 
cells by a similar mechanism. SCP1 and HORMAD1 are 
involved in chromosome pairing in the context of meiosis, 
and their presence in somatic cells may deregulate mitosis. 
Interesting, meiotic proteins have been implicated in 
reducing polyploidy in cancer cells and may serve as a 
means to maintain the balance between increased genome 
instability driving genetic variation and decreased genome 
instability necessary for propagating these malignant 
clones [85-87]. 
A number of additional CT antigens as well as other 
proteins preferentially expressed in testis have been shown 
to support productive mitosis in cancer cells. For instance, 
FMR1NB-, NXF2- STARD6- and FSIP1-depletion in lung 
cancer cells enhanced the occurrence of mitotic arrest and 
micronucleation in response to induction of mitotic stress 
induced by Paclitaxel or Nocodazole treatment [88, 89]. 
Thus, selected CT antigens may be essential for mitotic 
fidelity and resistance to chemotherapeutics in cancer 
cells. Interestingly, overexpression of NXF2, STARD6 and 
FSIP1 also induced mitotic defects, and we have recently 
shown that the overexpression of the SSX2 CT antigen is 
associated with mitotic aberrations and genomic instability 
[45]. These results suggest that multiple CT antigens and 
testis proteins support delicate processes in cancer cells 
that, when disturbed, lead to aberrant mitotic phenotypes 
[88]. Such CT antigens may represent novel targets for 
anti-cancer therapy.
ONcOGENIc cANcEr/tEstIs ANtIGENs 
As tArGEts FOr IMMUNOtHErAPY
cancer/testis antigen vaccination
The immunogenicity and cancer-specificity of CT 
antigens have made them prioritized targets for cancer 
immunotherapy, and their therapeutic function has 
been tested in a variety of clinical settings (reviewed in 
Gjerstorff et al. [90]). For historical reasons, MAGE-A 
and NY-ESO-1 in particular have been tested extensively 
as components in therapeutic cancer vaccines (Figure 
3). CT antigen vaccines are generally well-tolerated, 
and immunological responses as well as some clinical 
responses have been obtained. There are presently a large 
number of ongoing cancer vaccination trials assessing the 
therapeutic efficacy of CT antigens. For instance, 35 open 
clinical studies on NY-ESO-1 are listed at http://www.
clinicaltrials.gov. Some of the investigated CT antigens 
have known oncogenic effects (e.g. MAGE-A, MAGE-C2, 
SSX2, PRAME), whereas the functions in cancer of some 
CT antigens such as NY-ESO-1 remain unknown. 
Several recent clinical trials have provided 
encouraging results. Treatment of advanced melanoma 
and ovarian cancer patients with a recombinant fowlpox-
NY-ESO-1 vaccine resulted in NY-ESO-1 antibody and 
CD4+ and CD8+ T-cell responses in the majority of these 
patients, and CD8+ responses correlated with progression-
free survival [91, 92]. Another study tested the interesting 
approach of delivering NY-ESO-1 to dendritic cells by 
fusing the antigen to an antibody specific for the dendritic 
cell surface molecule, CD205, in combination with Toll-
like receptor agonists. Again, humoral and T-cell responses 
were obtained in patients with mixed advanced cancers, 
and 13 of 42 patients experienced disease stabilization 
[93]. This study also suggested that this treatment 
enhanced the effect of subsequent treatment with CTLA-4 
immune checkpoint inhibitors. 
The most comprehensive investigation used 
MAGE-A3 as a vaccine target in a randomized, double-
blinded, placebo-controlled phase III study in 2,272 non-
small cell lung cancer (NSCLC) patients (MAGRIT). 
Recombinant MAGE-A3-influenzae protein D fusion 
protein and the immunostimulant AS15 were administered 
to patients in up to 13 intramuscular injections over 
a period of 27 months. Unfortunately, this trial was 
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terminated in March 2014 (ESMO Congress 2014, 
Abstract 1173O), since it was shown that the vaccine 
did not significantly extend disease-free survival (DFS) 
compared to placebo. The same vaccine was also tested in 
another phase III clinical trial in 1,345 MAGE-A3-positive 
melanoma patients (DERMA), and this likewise failed 
with no improvement in DFS in the overall population 
(http://www.gsk.com). Why these two clinical studies 
were unsuccessful remains to be clearly determined, but 
the failure to induce sufficient cell-mediated responses 
may result from either the generally low immunogenicity 
of MAGE-A3 or the inability of the chosen vaccine design 
to break immune tolerance. The lack of effect may indeed 
advocate the need for more careful selection of tumor 
antigen targets. MAGE-A3 has been the most widely 
studied CT-antigen, but has only been shown to exhibit 
low immunogenicity. In addition, although MAGE-A3 
has been demonstrated to possess tumor-promoting 
capabilities, functional studies have only been performed 
with thyroid and pituitary cancer cells [94, 95] and, to our 
knowledge, functional studies on MAGE-A3 have not 
been performed using NSCLC or melanoma cells. 
Thus far, the majority of anti-cancer vaccination 
trials have targeted only a single antigen. However, recent 
data suggests that the clinical impact of immunotherapy 
increases by the inclusion of several antigens [96]. Thus, 
an exciting strategy would be to co-target biologically-
connected proteins, e.g. several CT antigens involved in 
cancer cell survival, in a multi-epitope setting. This may 
increase the magnitude and flexibility of the vaccine-
induced anti-tumor response and prevent the escape of 
tumor cells that would otherwise occur through selective 
loss of single target antigens. Although multiple CT 
antigens are up-regulated in many cancers, the amount of 
each antigen differs within individual cancer cells in the 
same tumor and between tumors of different patients with 
the same cancer type. Therefore, simultaneous targeting 
of these proteins may be a more effective strategy than 
targeting either molecule alone. It is not presently known 
how the redundancy of the many MAGE-A proteins or 
additional co-expressed CT antigens in regulation of 
survival pathways may affect tumor responsiveness 
Figure 3: cancer immunotherapies targeting cancer/testis antigens. The goal of therapeutic cancer immunotherapy is to reverse 
immune escape of tumor cells by overcoming tolerance and increasing numbers of tumor-reactive T cells. This can be accomplished 
by boosting existing immune responses to tumor antigens, and cancer/testis antigens have proved useful as targets due to high tumor-
specificity and immunogenicity. Currently two types of cancer/testis antigen-specific immunotherapy are used: vaccination and adoptive 
transfer. Vaccination stimulates the patient’s intrinsic immune response to cancer/testis antigens expressed by their tumor by administration 
of immunogenic peptides/proteins loaded on dendritic cells or in combination with adjuvants. Cancer/testis antigens are also popular targets 
for adoptive transfer wherein recombinant T-cell receptors specific for cancer/testis antigen epitopes are inserted into patient T cells, which 
are then expanded and transferred back to patients. Targeting oncogenic cancer/testis antigens in vaccination and adoptive transfer regimens 
may greatly reduce the risk of outgrowth of escape variants.
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to anti-MAGE-A3 treatment. In that respect, it will be 
interesting to see the outcome of ongoing trails evaluating 
the effect of vaccines targeting multiple antigens affecting 
cancer cell growth and survival. In a completed, but 
unreported, study, several MAGE family members (i.e. 
MAGE-A1, MAGE-A3, MAGE-A4, MAGE-A10 and 
MAGE-C2) were targeted simultaneously in melanoma 
patients using a peptide vaccine. Additional studies will 
target different proteins affecting proliferation and survival 
using autologous T cells (i.e. MAGE-A4, SSX, PRAME 
and survivin) in lymphoma, myeloma and mixed solid 
cancer patients (http://www.clinicaltrials.gov identifiers: 
NCT00365937, NCT01333046, NCT02239861, 
NCT02291848). Future studies should focus on regimens 
integrating emerging knowledge about tumor antigen 
function and immune stimulation to generate optimal anti-
tumor responses. 
Although individualized cancer vaccines targeting 
mutation antigens are currently receiving a great deal of 
attention, there may be several advantages of polyvalent 
CT antigen vaccines. The use of shared antigens, such 
as oncogenic CT antigens, as vaccine targets does not 
necessitate the tedious and time-consuming genome 
sequencing required to identify patient-specific antigens 
and antigen synthesis. Polyvalent CT antigen vaccines can 
be administered early after diagnosis and prevent further 
progression of the tumor before initiation of treatment. 
Furthermore, CT antigens may be preferred targets for 
types of cancer with low prevalence of somatic mutations 
[97].
cancer/testis antigens for adoptive t-cell therapy
Administration of in vitro expanded infiltrating T 
cells from melanoma tumors following myeloablative 
lymphodepleting regimens have been shown to induce 
tumor regression in more than 50% of patients with 
metastatic melanoma, and durable complete responses 
have also been achieved [98]. A similar approach for other 
types of human cancer is complicated by the difficulties 
with obtaining tumor-infiltrating lymphocytes. To expand 
this approach to a broader patient population, tumor-
reactive T cells can be generated by genetically modifying 
autologous T cells to express recombinant or chimeric 
T-cell receptors directed against common tumor antigens, 
a type of therapy for which CT antigens are among the 
high priority targets (Figure 3). Their frequent expression 
in many types of cancer makes CT antigen-directed T-cell 
therapy applicable to many patients, and their restriction 
in normal tissues to the HLA class I-negative germ cells 
likely prevents adverse effects. T-cell receptors against 
epitopes from MAGE-A4, NY-ESO-1 and SSX2 have been 
developed and are currently under evaluation for clinical 
function [99-101]. Preliminary results have demonstrated 
that clinical responses can indeed be achieved with CT 
antigen-directed T-cell therapy. For instance, patients with 
NY-ESO-1-positive melanoma and synovial sarcoma 
receiving autologous T cells transduced with an NY-
ESO-1-specific T-cell receptor demonstrated clinical 
responses in 55% and 61% of the cases, respectively. 
This strategy did not cause any cytotoxicity in patients. 
However, other clinical trials with modified autologous T 
cells have highlighted the importance of target specificity. 
Although MAGE-A3 exhibits high cancer cell specificity, 
severe toxicity of MAGE-A3-directed T-cell therapy has 
been reported in two instances. In one trial, two patients 
died from severe brain damage apparently due to cross-
reactivity of the T-cell receptor-transduced PBMCs with 
a highly similar epitope from MAGE-A12, which is 
expressed in tissues of the normal brain [102]. Similarly, 
two patients experienced cardiac arrest after treatment 
with autologous PBMCs transduced with a modified 
MAGE-A3 T-cell receptor, which apparently cross-reacted 
with an epitope of the cardiac protein titin [103, 104]. 
Although these unfortunate events can be attributed to the 
lack of T-cell receptor-specificity, they also emphasize the 
need for absolute target-specificity, suggesting that CT 
antigens and mutation antigens may be appropriate targets 
for this highly potent strategy. 
cOMbINAtION tHErAPIEs WItH 
ONcOGENIc cANcEr/tEstIs ANtIGENs
Strategies that combine current knowledge 
of conventional treatments with data on how these 
treatments impact the T cell population and the immune 
system are important elements in the development and 
optimization of novel treatment regimens, which should 
also include novel insight into the biology of CT antigens. 
Chemotherapeutic agents impact not only tumor cell 
proliferation but also cell survival, and it is evident that 
various drugs can kill tumor cells by activation of common 
apoptotic pathways. Essentially all cytotoxic anticancer 
drugs, e.g. microtubule binding drugs, DNA-damaging 
agents and nucleosides, induce apoptosis of malignant 
cells, but drug resistance is a major limiting factor of 
chemotherapeutics that may also lead to cross-resistance 
to other drugs with different mechanisms of action [105]. 
Cancer-associated defects in apoptosis play a vital role in 
drug resistance [106]. Interestingly, as described above, 
several CT antigens have been associated with impaired 
apoptosis [51-61, 63, 66]. Anti-apoptotic CT antigens are 
prime candidates for immunotherapy since they facilitate 
the escape of malignant cells from cytotoxic therapies. 
Thus, the combination of immunotherapy targeting anti-
apoptotic CT antigens with conventional chemotherapy 
appears to be highly synergistic. In an ideal combinational 
therapeutic setting, conventional therapy would kill 
the majority of the cancer cells, leaving only cells that 
express high levels of CT antigens, which would be 
particularly vulnerable to killing by therapy-induced CT 
antigen-specific T cells (Figure 4A). The synergy of these 
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Figure 4: targeting oncogenic cancer/testis antigen in combination with other therapies. A. Chemotherapy may only kill 
the bulk of tumor cells, leaving chemoresistant cells. Since several cancer/testis antigens have been demonstrated to inhibit apoptosis in 
cancer cells and lower the response to cytotoxic anti-cancer drugs, targeting cancer/testis antigens in combination with chemotherapy may 
be effective. b. DNA methyltranferase (DNMT) inhibitors, which have been approved for treatment of hematologic malignancies, can 
induce cancer/testis antigen expression in cancer cells and reverse intratumoral heterogeneity. Thus, treatment with DNMT inhibitors may 
boost the effect of vaccines targeting oncogenic cancer/testis antigens. c. The foremost limitation to expanding adoptive transfer of T cells 
to treatment of multiple types of human cancer is the need for sufficient numbers of tumor-infiltrating T cells. Vaccination with cancer/
testis antigens expressed in the tumor can increase these numbers in cancer types wherein such cells are sparse. Thus, the combination of 
adoptive transfer and cancer/testis antigen vaccination may be beneficial. D. Tumor antigen vaccination can enhance the effect of immune-
checkpoint blockade, and directing the immune response to antigens important for the tumor cells, such as oncogenic cancer/testis antigens, 
may further enhance the effect of this combination treatment. 
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measures would, consequently, result in a more effective 
treatment than either regime alone.
Spontaneous immunity against CT antigens can 
be introduced as a response to treatment with DNA 
methyltransferase (DNMT) inhibitors, such as 5-aza-
2’-deoxycytidine (5-aza-2’-CdR) or 5-azacytidine 
[107, 108], which have been approved for treatment of 
hematologic malignancies and may also be useful for 
solid cancers. These agents have the ability to reverse 
epigenetic silencing of genes in cancer cells and restore 
normal function of multiple cellular processes, including 
cell-cycle regulation, apoptosis and immune recognition 
[109, 110]. DNMT inhibitors have been described to up-
regulate expression of many CT antigens, e.g. MAGE, 
GAGE, NY-ESO-1 and PRAME [107], and such up-
regulation has been associated with induction of MAGE-
specific T-cell responses in acute myeloid leukemia and 
myeloid dysplastic syndrome patients [107]. Furthermore, 
PRAME antigen-specific killing of malignant cell lines by 
low-avidity CTL clones have been shown to be increased 
following treatment with DNMT inhibitors [111]. The 
clinical and prognostic significance of these CT-antigen-
specific T-cell responses on the clinical efficacy of 
DNMT inhibitor treatment in hematologic malignancies 
remains to be defined, although it suggests that combining 
DNMT inhibitors with vaccination to induce CT antigen 
expression in both tumors and CT antigen-specific T cells 
may prove beneficial (Figure 4B). However, as novel 
insight has demonstrated that some CT antigens can also 
confer tumorigenic properties to cancer cells, DNMT 
inhibitors should be used with caution. Although the net 
result seems to be an inhibitory effect on tumor function, 
there may be unidentified deleterious effects, such as 
enhanced EMT, which supports metastasis.
Another utilization of the up-regulation of CT 
antigens by DNMT inhibitors may be combining DNMT 
inhibitors with adoptive transfer of CT-specific T cells. 
Accordingly, the combination of adoptive transfer 
of MAGE-A4-specific T cells with 5-aza-2’-CdR in 
patients with Hodgkin’s lymphoma generated MAGE-
A4-specific T cells and increased their anti-tumor T-cell 
repertoire [112]. Similarly, combinations of DNMT 
inhibition and CT antigen vaccination may enhance the 
frequency of tumor-specific T cells in tumors and thereby 
support adoptive T-cell transfer regimens (Figure 4C). As 
described above, genetically modifying autologous T cells 
to express recombinant T-cell receptors is an additional 
approach to target CT antigens, and may also naturally 
function synergistically with DNMT inhibition.
Antibodies that block the function of immune 
checkpoint molecules (i.e. CTLA-4 and PD1), resulting 
in T-cell activation, have greatly improved survival in 
metastatic melanoma as well as NSCLC, and are being 
tested for treatment of several additional types of cancer 
[113-115]. This demonstrates that the immune system 
can be modulated to effectively control tumor growth, 
although a significant number of patients do not respond to 
this treatment or experience relapse. Recent results suggest 
that augmented anti-tumor effects can be obtained by 
combining immune checkpoint blockade with vaccination 
[93, 116-119]. Thus, vaccination with CT antigens, and 
oncogenic CT antigens in particular, should clearly be 
considered in combination with immune checkpoint 
inhibition for enhanced effects (Figure 4D). 
cONcLUsIONs
The frequent use of CT antigens in vaccination 
trials have been based on their high cancer specificity, 
immunogenicity and relatively frequent expression in 
many different types of human cancer. As discussed in 
this review, recent results show that multiple CT antigens 
exhibit characteristics important for tumorigenesis, 
suggesting that targeting such oncogenic CT antigens 
may control cancer development. For instance, the 
targeting of CT antigens that enhance cancer cell growth 
and/or survival would diminish the tumorigenic potential. 
Likewise, targeting of CT antigens that promote EMT 
may reduce the risk of metastases. Thus, oncogenicity 
should be considered an important criterion for selection 
of CT antigens for future immunotherapy, and functional 
characterization of CT antigens should be of high priority 
in order to identify more oncogenic CT antigen targets 
or CT antigens expressed by cancer cell subpopulations 
important for tumor initiation and progression. 
Recent advances in breaking immune tolerance 
in cancer patients using immune checkpoint inhibitors 
has set the stage for immune targeting as a supplement 
to conventional treatment of human cancer, and a 
significant effort remains to further improve efficacy and 
specificity of treatment. Overall, the synergistic effects of 
conventional and immunological therapies necessitate re-
thinking current clinical strategies both with respect to the 
chosen chemotherapeutics and the design of the selected 
immunotherapy. Thus, targeting oncogenic CT antigens 
seems to be a promising, broadly applicable approach 
that can synergistically be combined with conventional 
cytotoxic therapies or novel types of immunotherapy such 




1. Chen YT, Hsu M, Lee P, Shin SJ, Mhawech-Fauceglia P, 
Odunsi K, Altorki NK, Song CJ, Jin BQ, Simpson AJ and 
Old LJ. Cancer/testis antigen CT45: analysis of mRNA and 
protein expression in human cancer. International journal 
of cancer Journal international du cancer. 2009; 124:2893-
2898.
Oncotarget15782www.impactjournals.com/oncotarget
2. dos Santos NR, Torensma R, de Vries TJ, Schreurs MW, 
de Bruijn DR, Kater-Baats E, Ruiter DJ, Adema GJ, van 
Muijen GN and van Kessel AG. Heterogeneous expression 
of the SSX cancer/testis antigens in human melanoma 
lesions and cell lines. Cancer research. 2000; 60:1654-1662.
3. Hofmann O, Caballero OL, Stevenson BJ, Chen YT, 
Cohen T, Chua R, Maher CA, Panji S, Schaefer U, Kruger 
A, Lehvaslaiho M, Carninci P, Hayashizaki Y, Jongeneel 
CV, Simpson AJ, Old LJ, et al. Genome-wide analysis of 
cancer/testis gene expression. Proceedings of the National 
Academy of Sciences of the United States of America. 
2008; 105:20422-20427.
4. Sahin U, Tureci O, Chen YT, Seitz G, Villena-Heinsen C, 
Old LJ and Pfreundschuh M. Expression of multiple cancer/
testis (CT) antigens in breast cancer and melanoma: basis 
for polyvalent CT vaccine strategies. International journal 
of cancer Journal international du cancer. 1998; 78:387-
389.
5. Zendman AJ, de Wit NJ, van Kraats AA, Weidle UH, 
Ruiter DJ and van Muijen GN. Expression profile of genes 
coding for melanoma differentiation antigens and cancer/
testis antigens in metastatic lesions of human cutaneous 
melanoma. Melanoma research. 2001; 11:451-459.
6. Gjerstorff MF, Johansen LE, Nielsen O, Kock K and 
Ditzel HJ. Restriction of GAGE protein expression to 
subpopulations of cancer cells is independent of genotype 
and may limit the use of GAGE proteins as targets for 
cancer immunotherapy. British journal of cancer. 2006; 
94:1864-1873.
7. Greve KB, Pohl M, Olsen KE, Nielsen O, Ditzel HJ and 
Gjerstorff MF. SSX2-4 expression in early-stage non-small 
cell lung cancer. Tissue antigens. 2014; 83:344-349.
8. Janitz M, Fiszer D, Michalczak-Janitz K, Lukaszyk A, 
Fernandez N, Skorupski W and Kurpisz M. Analysis 
of mRNA for class I HLA on human gametogenic cells. 
Molecular reproduction and development. 1994; 38:231-
237.
9. Fijak M and Meinhardt A. The testis in immune privilege. 
Immunological reviews. 2006; 213:66-81.
10. Gotter J, Brors B, Hergenhahn M and Kyewski B. 
Medullary epithelial cells of the human thymus express a 
highly diverse selection of tissue-specific genes colocalized 
in chromosomal clusters. The Journal of experimental 
medicine. 2004; 199:155-166.
11. Tsuji T, Altorki NK, Ritter G, Old LJ and Gnjatic S. 
Characterization of preexisting MAGE-A3-specific CD4+ 
T cells in cancer patients and healthy individuals and their 
activation by protein vaccination. Journal of immunology. 
2009; 183:4800-4808.
12. Andersen RS, Thrue CA, Junker N, Lyngaa R, Donia M, 
Ellebaek E, Svane IM, Schumacher TN, Thor Straten P 
and Hadrup SR. Dissection of T-cell antigen specificity in 
human melanoma. Cancer research. 2012; 72:1642-1650.
13. Wang Y, Wu XJ, Zhao AL, Yuan YH, Chen YT, Jungbluth 
AA, Gnjatic S, Santiago D, Ritter G, Chen WF, Old LJ 
and Ji JF. Cancer/testis antigen expression and autologous 
humoral immunity to NY-ESO-1 in gastric cancer. Cancer 
immunity. 2004; 4:11.
14. Akcakanat A, Kanda T, Koyama Y, Watanabe M, Kimura 
E, Yoshida Y, Komukai S, Nakagawa S, Odani S, Fujii 
H and Hatakeyama K. NY-ESO-1 expression and its 
serum immunoreactivity in esophageal cancer. Cancer 
chemotherapy and pharmacology. 2004; 54:95-100.
15. Ayyoub M, Rimoldi D, Guillaume P, Romero P, Cerottini 
JC, Valmori D and Speiser D. Tumor-reactive, SSX-2-
specific CD8+ T cells are selectively expanded during 
immune responses to antigen-expressing tumors in 
melanoma patients. Cancer research. 2003; 63:5601-5606.
16. Gnjatic S, Atanackovic D, Jager E, Matsuo M, Selvakumar 
A, Altorki NK, Maki RG, Dupont B, Ritter G, Chen YT, 
Knuth A and Old LJ. Survey of naturally occurring CD4+ 
T cell responses against NY-ESO-1 in cancer patients: 
correlation with antibody responses. Proceedings of the 
National Academy of Sciences of the United States of 
America. 2003; 100:8862-8867.
17. Qian F, Gnjatic S, Jager E, Santiago D, Jungbluth A, Grande 
C, Schneider S, Keitz B, Driscoll D, Ritter G, Lele S, Sood 
A, Old LJ and Odunsi K. Th1/Th2 CD4+ T cell responses 
against NY-ESO-1 in HLA-DPB1*0401/0402 patients with 
epithelial ovarian cancer. Cancer immunity. 2004; 4:12.
18. Milne K, Barnes RO, Girardin A, Mawer MA, Nesslinger 
NJ, Ng A, Nielsen JS, Sahota R, Tran E, Webb JR, Wong 
MQ, Wick DA, Wray A, McMurtrie E, Kobel M, Kalloger 
SE, et al. Tumor-infiltrating T cells correlate with NY-ESO-
1-specific autoantibodies in ovarian cancer. PloS one. 2008; 
3:e3409.
19. Rooney MS, Shukla SA, Wu CJ, Getz G and Hacohen N. 
Molecular and genetic properties of tumors associated with 
local immune cytolytic activity. Cell. 2015; 160:48-61.
20. Hanahan D and Weinberg RA. The hallmarks of cancer. 
Cell. 2000; 100:57-70.
21. Hanahan D and Weinberg RA. Hallmarks of cancer: the 
next generation. Cell. 2011; 144:646-674.
22. Schreiber RD, Old LJ and Smyth MJ. Cancer 
immunoediting: integrating immunity’s roles in cancer 
suppression and promotion. Science. 2011; 331:1565-1570.
23. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De 
Plaen E, Van den Eynde B, Knuth A and Boon T. A gene 
encoding an antigen recognized by cytolytic T lymphocytes 
on a human melanoma. Science. 1991; 254:1643-1647.
24. Park S, Lim Y, Lee D, Cho B, Bang YJ, Sung S, Kim HY, 
Kim DK, Lee YS, Song Y and Jeoung DI. Identification 
and characterization of a novel cancer/testis antigen gene 
CAGE-1. Biochimica et biophysica acta. 2003; 1625:173-
182.
25. Chen YT, Gure AO, Tsang S, Stockert E, Jager E, Knuth A 
and Old LJ. Identification of multiple cancer/testis antigens 
by allogeneic antibody screening of a melanoma cell line 
Oncotarget15783www.impactjournals.com/oncotarget
library. Proceedings of the National Academy of Sciences 
of the United States of America. 1998; 95:6919-6923.
26. Jager D, Unkelbach M, Frei C, Bert F, Scanlan MJ, Jager 
E, Old LJ, Chen YT and Knuth A. Identification of tumor-
restricted antigens NY-BR-1, SCP-1, and a new cancer/
testis-like antigen NW-BR-3 by serological screening 
of a testicular library with breast cancer serum. Cancer 
immunity. 2002; 2:5.
27. De Backer O, Arden KC, Boretti M, Vantomme V, De 
Smet C, Czekay S, Viars CS, De Plaen E, Brasseur F, 
Chomez P, Van den Eynde B, Boon T and van der Bruggen 
P. Characterization of the GAGE genes that are expressed 
in various human cancers and in normal testis. Cancer 
research. 1999; 59:3157-3165.
28. Chen YT, Scanlan MJ, Sahin U, Tureci O, Gure AO, Tsang 
S, Williamson B, Stockert E, Pfreundschuh M and Old LJ. 
A testicular antigen aberrantly expressed in human cancers 
detected by autologous antibody screening. Proceedings of 
the National Academy of Sciences of the United States of 
America. 1997; 94:1914-1918.
29. Scanlan MJ, Gordon CM, Williamson B, Lee SY, Chen 
YT, Stockert E, Jungbluth A, Ritter G, Jager D, Jager E, 
Knuth A and Old LJ. Identification of cancer/testis genes 
by database mining and mRNA expression analysis. 
International journal of cancer Journal international du 
cancer. 2002; 98:485-492.
30. Yokoe T, Tanaka F, Mimori K, Inoue H, Ohmachi T, 
Kusunoki M and Mori M. Efficient identification of a novel 
cancer/testis antigen for immunotherapy using three-step 
microarray analysis. Cancer research. 2008; 68:1074-1082.
31. Chen YT, Venditti CA, Theiler G, Stevenson BJ, Iseli 
C, Gure AO, Jongeneel CV, Old LJ and Simpson AJ. 
Identification of CT46/HORMAD1, an immunogenic 
cancer/testis antigen encoding a putative meiosis-related 
protein. Cancer immunity. 2005; 5:9.
32. Chen YT, Scanlan MJ, Venditti CA, Chua R, Theiler G, 
Stevenson BJ, Iseli C, Gure AO, Vasicek T, Strausberg RL, 
Jongeneel CV, Old LJ and Simpson AJ. Identification of 
cancer/testis-antigen genes by massively parallel signature 
sequencing. Proceedings of the National Academy of 
Sciences of the United States of America. 2005; 102:7940-
7945.
33. Almeida LG, Sakabe NJ, deOliveira AR, Silva MC, 
Mundstein AS, Cohen T, Chen YT, Chua R, Gurung S, 
Gnjatic S, Jungbluth AA, Caballero OL, Bairoch A, Kiesler 
E, White SL, Simpson AJ, et al. CTdatabase: a knowledge-
base of high-throughput and curated data on cancer-testis 
antigens. Nucleic acids research. 2009; 37:D816-819.
34. Stevenson BJ, Iseli C, Panji S, Zahn-Zabal M, Hide W, 
Old LJ, Simpson AJ and Jongeneel CV. Rapid evolution of 
cancer/testis genes on the X chromosome. BMC Genomics. 
2007; 8:129.
35. Zhang Q and Su B. Evolutionary origin and human-specific 
expansion of a cancer/testis antigen gene family. Molecular 
biology and evolution. 2014; 31:2365-2375.
36. Sang M, Wang L, Ding C, Zhou X, Wang B, Wang L, Lian 
Y and Shan B. Melanoma-associated antigen genes - an 
update. Cancer letters. 2011; 302:85-90.
37. Liu Y, Zhu Q and Zhu N. Recent duplication and positive 
selection of the GAGE gene family. Genetica. 2008; 
133:31-5.
38. Gjerstorff MF and Ditzel HJ. An overview of the GAGE 
cancer/testis antigen family with the inclusion of newly 
identified members. Tissue antigens. 2008; 71:187-192.
39. Killen MW, Taylor TL, Stults DM, Jin W, Wang 
LL, Moscow JA and Pierce AJ. Configuration and 
rearrangement of the human GAGE gene clusters. American 
journal of translational research. 2011; 3:234-242.
40. Gjerstorff MF and Ditzel HJ. Limited SP17 expression 
within tumors diminishes its therapeutic potential. Tissue 
antigens. 2012; 80:523-527.
41. Mamsen LS, Brochner CB, Byskov AG and Mollgard K. 
The migration and loss of human primordial germ stem 
cells from the hind gut epithelium towards the gonadal 
ridge. The International journal of developmental biology. 
2012; 56:771-778.
42. Old LJ. Cancer is a somatic cell pregnancy. Cancer 
immunity. 2007; 7:19.
43. Silva WA, Jr., Gnjatic S, Ritter E, Chua R, Cohen T, Hsu 
M, Jungbluth AA, Altorki NK, Chen YT, Old LJ, Simpson 
AJ and Caballero OL. PLAC1, a trophoblast-specific cell 
surface protein, is expressed in a range of human tumors 
and elicits spontaneous antibody responses. Cancer 
immunity. 2007; 7:18.
44. Acevedo HF, Tong JY and Hartsock RJ. Human chorionic 
gonadotropin-beta subunit gene expression in cultured 
human fetal and cancer cells of different types and origins. 
Cancer. 1995; 76:1467-1475.
45. Greve KB, Lindgreen JN, Terp MG, Pedersen CB, Schmidt 
S, Mollenhauer J, Kristensen SB, Andersen RS, Relster 
MM, Ditzel HJ and Gjerstorff MF. Ectopic expression 
of cancer/testis antigen SSX2 induces DNA damage and 
promotes genomic instability. Mol Oncol. 2015; 9:437-449.
46. D’Arcy P, Maruwge W, Wolahan B, Ma L and Brodin B. 
Oncogenic Functions of the Cancer-Testis Antigen SSX 
on the Proliferation, Survival, and Signaling Pathways of 
Cancer Cells. PloS one. 2014; 9:e95136.
47. Gjerstorff MF, Relster MM, Greve KB, Moeller JB, Elias 
D, Lindgreen JN, Schmidt S, Mollenhauer J, Voldborg B, 
Pedersen CB, Bruckmann NH, Mollegaard NE and Ditzel 
HJ. SSX2 is a novel DNA-binding protein that antagonizes 
polycomb group body formation and gene repression. 
Nucleic Acids Res. 2014; 42:11433-46.
48. Mills AA. Throwing the cancer switch: reciprocal roles of 
polycomb and trithorax proteins. Nature reviews Cancer. 
2010; 10:669-682.
49. Por E, Byun HJ, Lee EJ, Lim JH, Jung SY, Park I, Kim 
YM, Jeoung DI and Lee H. The cancer/testis antigen CAGE 
with oncogenic potential stimulates cell proliferation by 
Oncotarget15784www.impactjournals.com/oncotarget
up-regulating cyclins D1 and E in an AP-1- and E2F-
dependent manner. The Journal of biological chemistry. 
2010; 285:14475-14485.
50. Kim Y, Park D, Kim H, Choi M, Lee H, Lee YS, Choe J, 
Kim YM and Jeoung D. miR-200b and cancer/testis antigen 
CAGE form a feedback loop to regulate the invasion and 
tumorigenic and angiogenic responses of a cancer cell line 
to microtubule-targeting drugs. The Journal of biological 
chemistry. 2013; 288:36502-36518.
51. Atanackovic D, Hildebrandt Y, Jadczak A, Cao Y, 
Luetkens T, Meyer S, Kobold S, Bartels K, Pabst C, 
Lajmi N, Gordic M, Stahl T, Zander AR, Bokemeyer C 
and Kroger N. Cancer-testis antigens MAGE-C1/CT7 and 
MAGE-A3 promote the survival of multiple myeloma cells. 
Haematologica. 2010; 95:785-793.
52. Weeraratne SD, Amani V, Neiss A, Teider N, Scott 
DK, Pomeroy SL and Cho YJ. miR-34a confers 
chemosensitivity through modulation of MAGE-A and p53 
in medulloblastoma. Neuro-oncology. 2011; 13:165-175.
53. Nardiello T, Jungbluth AA, Mei A, Diliberto M, Huang 
X, Dabrowski A, Andrade VC, Wasserstrum R, Ely 
S, Niesvizky R, Pearse R, Coleman M, Jayabalan DS, 
Bhardwaj N, Old LJ, Chen-Kiang S, et al. MAGE-A 
inhibits apoptosis in proliferating myeloma cells through 
repression of Bax and maintenance of survivin. Clinical 
cancer research : an official journal of the American 
Association for Cancer Research. 2011; 17:4309-4319.
54. Bhatia N, Xiao TZ, Rosenthal KA, Siddiqui IA, 
Thiyagarajan S, Smart B, Meng Q, Zuleger CL, Mukhtar H, 
Kenney SC, Albertini MR and Jack Longley B. MAGE-C2 
promotes growth and tumorigenicity of melanoma cells, 
phosphorylation of KAP1, and DNA damage repair. The 
Journal of investigative dermatology. 2013; 133:759-767.
55. Kasuga C, Nakahara Y, Ueda S, Hawkins C, Taylor MD, 
Smith CA and Rutka JT. Expression of MAGE and GAGE 
genes in medulloblastoma and modulation of resistance 
to chemotherapy. Laboratory investigation. Journal of 
neurosurgery Pediatrics. 2008; 1:305-313.
56. Yang B, O’Herrin S, Wu J, Reagan-Shaw S, Ma Y, Nihal 
M and Longley BJ. Select cancer testes antigens of the 
MAGE-A, -B, and -C families are expressed in mast cell 
lines and promote cell viability in vitro and in vivo. The 
Journal of investigative dermatology. 2007; 127:267-275.
57. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi 
S, Pierotti MA, Rodolfo M and Schneider C. MAGE-A 
tumor antigens target p53 transactivation function through 
histone deacetylase recruitment and confer resistance to 
chemotherapeutic agents. Proceedings of the National 
Academy of Sciences of the United States of America. 
2006; 103:11160-11165.
58. Doyle JM, Gao J, Wang J, Yang M and Potts PR. MAGE-
RING protein complexes comprise a family of E3 ubiquitin 
ligases. Molecular cell. 2010; 39:963-974.
59. Yang B, O’Herrin SM, Wu J, Reagan-Shaw S, Ma Y, 
Bhat KM, Gravekamp C, Setaluri V, Peters N, Hoffmann 
FM, Peng H, Ivanov AV, Simpson AJ and Longley 
BJ. MAGE-A, mMage-b, and MAGE-C proteins form 
complexes with KAP1 and suppress p53-dependent 
apoptosis in MAGE-positive cell lines. Cancer research. 
2007; 67:9954-9962.
60. Marcar L, Maclaine NJ, Hupp TR and Meek DW. Mage-A 
cancer/testis antigens inhibit p53 function by blocking 
its interaction with chromatin. Cancer research. 2010; 
70:10362-10370.
61. Cilensek ZM, Yehiely F, Kular RK and Deiss LP. A 
member of the GAGE family of tumor antigens is an anti-
apoptotic gene that confers resistance to Fas/CD95/APO-1, 
Interferon-gamma, taxol and gamma-irradiation. Cancer 
Biol Ther. 2002; 1:380-387.
62. Kular RK, Yehiely F, Kotlo KU, Cilensek ZM, Bedi R 
and Deiss LP. GAGE, an antiapoptotic protein binds and 
modulates the expression of nucleophosmin/B23 and 
interferon regulatory factor 1. Journal of interferon & 
cytokine research : the official journal of the International 
Society for Interferon and Cytokine Research. 2009; 
29:645-655.
63. Zeng Y, He Y, Yang F, Mooney SM, Getzenberg RH, 
Orban J and Kulkarni P. The cancer/testis antigen prostate-
associated gene 4 (PAGE4) is a highly intrinsically 
disordered protein. The Journal of biological chemistry. 
2011; 286:13985-13994.
64. Smith SK and Kipling D. The role of replicative senescence 
in cancer and human ageing: utility (or otherwise) of murine 
models. Cytogenetic and genome research. 2004; 105:455-
463.
65. Peche LY, Scolz M, Ladelfa MF, Monte M and Schneider 
C. MageA2 restrains cellular senescence by targeting the 
function of PMLIV/p53 axis at the PML-NBs. Cell death 
and differentiation. 2012; 19:926-936.
66. Kim Y, Park H, Park D, Lee YS, Choe J, Hahn JH, Lee H, 
Kim YM and Jeoung D. Cancer/testis antigen CAGE exerts 
negative regulation on p53 expression through HDAC2 
and confers resistance to anti-cancer drugs. The Journal of 
biological chemistry. 2010; 285:25957-25968.
67. Wong PP, Yeoh CC, Ahmad AS, Chelala C, Gillett C, 
Speirs V, Jones JL and Hurst HC. Identification of MAGEA 
antigens as causal players in the development of tamoxifen-
resistant breast cancer. Oncogene. 2014; 33:4579-4588.
68. Suyama T, Shiraishi T, Zeng Y, Yu W, Parekh N, Vessella 
RL, Luo J, Getzenberg RH and Kulkarni P. Expression of 
cancer/testis antigens in prostate cancer is associated with 
disease progression. The Prostate. 2010; 70:1778-1787.
69. Jungbluth AA, Ely S, DiLiberto M, Niesvizky R, 
Williamson B, Frosina D, Chen YT, Bhardwaj N, Chen-
Kiang S, Old LJ and Cho HJ. The cancer-testis antigens 
CT7 (MAGE-C1) and MAGE-A3/6 are commonly 
expressed in multiple myeloma and correlate with plasma-
cell proliferation. Blood. 2005; 106:167-174.
70. Zendman AJ, van Kraats AA, den Hollander AI, Weidle 
Oncotarget15785www.impactjournals.com/oncotarget
UH, Ruiter DJ and van Muijen GN. Characterization 
of XAGE-1b, a short major transcript of cancer/testis-
associated gene XAGE-1, induced in melanoma metastasis. 
International journal of cancer Journal international du 
cancer. 2002; 97:195-204.
71. Barrow C, Browning J, MacGregor D, Davis ID, Sturrock 
S, Jungbluth AA and Cebon J. Tumor antigen expression in 
melanoma varies according to antigen and stage. Clinical 
cancer research : an official journal of the American 
Association for Cancer Research. 2006; 12:764-771.
72. Luftl M, Schuler G and Jungbluth AA. Melanoma or not? 
Cancer testis antigens may help. The British journal of 
dermatology. 2004; 151:1213-1218.
73. Yang F, Zhou X, Miao X, Zhang T, Hang X, Tie R, Liu 
N, Tian F, Wang F and Yuan J. MAGEC2, an epithelial-
mesenchymal transition inducer, is associated with breast 
cancer metastasis. Breast cancer research and treatment. 
2014; 145:23-32.
74. Shang B, Gao A, Pan Y, Zhang G, Tu J, Zhou Y, Yang 
P, Cao Z, Wei Q, Ding Y, Zhang J, Zhao Y and Zhou 
Q. CT45A1 acts as a new proto-oncogene to trigger 
tumorigenesis and cancer metastasis. Cell death & disease. 
2014; 5:e1285.
75. Caballero OL, Cohen T, Gurung S, Chua R, Lee P, Chen 
YT, Jat P and Simpson AJ. Effects of CT-Xp gene knock 
down in melanoma cell lines. Oncotarget. 2013; 4:531-541.
76. De Craene B and Berx G. Regulatory networks defining 
EMT during cancer initiation and progression. Nature 
reviews Cancer. 2013; 13:97-110.
77. Kim Y, Park H and Jeoung D. CAGE, a cancer/testis 
antigen, induces c-FLIP(L) and Snail to enhance cell 
motility and increase resistance to an anti-cancer drug. 
Biotechnology letters. 2009; 31:945-952.
78. Woods K, Pasam A, Jayachandran A, Andrews MC and 
Cebon J. Effects of epithelial to mesenchymal transition on 
T cell targeting of melanoma cells. Frontiers in oncology. 
2014; 4:367.
79. Bai Q, Assou S, Haouzi D, Ramirez JM, Monzo C, Becker 
F, Gerbal-Chaloin S, Hamamah S and De Vos J. Dissecting 
the first transcriptional divergence during human embryonic 
development. Stem cell reviews. 2012; 8:150-162.
80. Gjerstorff MF, Harkness L, Kassem M, Frandsen U, Nielsen 
O, Lutterodt M, Mollgard K and Ditzel HJ. Distinct GAGE 
and MAGE-A expression during early human development 
indicate specific roles in lineage differentiation. Human 
reproduction. 2008; 23:2194-2201.
81. Lee EK, Song KA, Chae JH, Kim KM, Kim SH and Kang 
MS. GAGE12 mediates human gastric carcinoma growth 
and metastasis. Int J Cancer. 2015; 136:2284-92.
82. Keeney S, Giroux CN and Kleckner N. Meiosis-specific 
DNA double-strand breaks are catalyzed by Spo11, a 
member of a widely conserved protein family. Cell. 1997; 
88:375-384.
83. Pousette A, Leijonhufvud P, Arver S, Kvist U, Pelttari J 
and Hoog C. Presence of synaptonemal complex protein 
1 transversal filament-like protein in human primary 
spermatocytes. Human reproduction. 1997; 12:2414-2417.
84. Keeney S. Spo11 and the Formation of DNA Double-Strand 
Breaks in Meiosis. Genome dynamics and stability. 2008; 
2:81-123.
85. Erenpreisa J and Cragg MS. MOS, aneuploidy and the 
ploidy cycle of cancer cells. Oncogene. 2010; 29:5447-
5451.
86. Ianzini F, Kosmacek EA, Nelson ES, Napoli E, Erenpreisa 
J, Kalejs M and Mackey MA. Activation of meiosis-specific 
genes is associated with depolyploidization of human tumor 
cells following radiation-induced mitotic catastrophe. 
Cancer research. 2009; 69:2296-2304.
87. Kalejs M, Ivanov A, Plakhins G, Cragg MS, Emzinsh D, 
Illidge TM and Erenpreisa J. Upregulation of meiosis-
specific genes in lymphoma cell lines following genotoxic 
insult and induction of mitotic catastrophe. BMC cancer. 
2006; 6:6.
88. Cappell KM, Sinnott R, Taus P, Maxfield K, Scarbrough 
M and Whitehurst AW. Multiple cancer testis antigens 
function to support tumor cell mitotic fidelity. Molecular 
and cellular biology. 2012; 32:4131-4140.
89. Whitehurst AW, Xie Y, Purinton SC, Cappell KM, Swanik 
JT, Larson B, Girard L, Schorge JO and White MA. Tumor 
antigen acrosin binding protein normalizes mitotic spindle 
function to promote cancer cell proliferation. Cancer 
research. 2010; 70:7652-7661.
90. Gjerstorff MF, Burns J and Ditzel HJ. Cancer-germline 
antigen vaccines and epigenetic enhancers: future strategies 
for cancer treatment. Expert opinion on biological therapy. 
2010; 10:1061-1075.
91. Odunsi K, Matsuzaki J, Karbach J, Neumann A, Mhawech-
Fauceglia P, Miller A, Beck A, Morrison CD, Ritter G, 
Godoy H, Lele S, duPont N, Edwards R, Shrikant P, Old LJ, 
Gnjatic S, et al. Efficacy of vaccination with recombinant 
vaccinia and fowlpox vectors expressing NY-ESO-1 antigen 
in ovarian cancer and melanoma patients. Proceedings of 
the National Academy of Sciences of the United States of 
America. 2012; 109:5797-5802.
92. Jager E, Karbach J, Gnjatic S, Neumann A, Bender A, 
Valmori D, Ayyoub M, Ritter E, Ritter G, Jager D, Panicali 
D, Hoffman E, Pan L, Oettgen H, Old LJ and Knuth A. 
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce 
both humoral and cellular NY-ESO-1-specific immune 
responses in cancer patients. Proceedings of the National 
Academy of Sciences of the United States of America. 
2006; 103:14453-14458.
93. Dhodapkar MV, Sznol M, Zhao B, Wang D, Carvajal RD, 
Keohan ML, Chuang E, Sanborn RE, Lutzky J, Powderly 
J, Kluger H, Tejwani S, Green J, Ramakrishna V, Crocker 
A, Vitale L, et al. Induction of antigen-specific immunity 
with a vaccine targeting NY-ESO-1 to the dendritic cell 
receptor DEC-205. Science translational medicine. 2014; 
6:232ra251.
Oncotarget15786www.impactjournals.com/oncotarget
94. Zhu X, Asa SL and Ezzat S. Fibroblast growth factor 2 
and estrogen control the balance of histone 3 modifications 
targeting MAGE-A3 in pituitary neoplasia. Clinical cancer 
research : an official journal of the American Association 
for Cancer Research. 2008; 14:1984-1996.
95. Liu W, Cheng S, Asa SL and Ezzat S. The melanoma-
associated antigen A3 mediates fibronectin-controlled 
cancer progression and metastasis. Cancer research. 2008; 
68:8104-8112.
96. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska 
A, Szczylik C, Staehler M, Brugger W, Dietrich PY, 
Mendrzyk R, Hilf N, Schoor O, Fritsche J, Mahr A, Maurer 
D, Vass V, et al. Multipeptide immune response to cancer 
vaccine IMA901 after single-dose cyclophosphamide 
associates with longer patient survival. Nature medicine. 
2012; 18:1254-1261.
97. Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, 
Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, 
Borresen-Dale AL, Boyault S, Burkhardt B, Butler AP, 
Caldas C, Davies HR, Desmedt C, et al. Signatures of 
mutational processes in human cancer. Nature. 2013; 
500:415-421.
98. Dudley ME, Yang JC, Sherry R, Hughes MS, Royal R, 
Kammula U, Robbins PF, Huang J, Citrin DE, Leitman 
SF, Wunderlich J, Restifo NP, Thomasian A, Downey 
SG, Smith FO, Klapper J, et al. Adoptive cell therapy for 
patients with metastatic melanoma: evaluation of intensive 
myeloablative chemoradiation preparative regimens. 
Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology. 2008; 26:5233-
5239.
99. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry 
RM, Dudley ME, Wunderlich JR, Nahvi AV, Helman 
LJ, Mackall CL, Kammula US, Hughes MS, Restifo NP, 
Raffeld M, Lee CC, Levy CL, et al. Tumor regression 
in patients with metastatic synovial cell sarcoma and 
melanoma using genetically engineered lymphocytes 
reactive with NY-ESO-1. Journal of clinical oncology 
: official journal of the American Society of Clinical 
Oncology. 2011; 29:917-924.
100. Abate-Daga D, Speiser DE, Chinnasamy N, Zheng Z, Xu H, 
Feldman SA, Rosenberg SA and Morgan RA. Development 
of a T cell receptor targeting an HLA-A*0201 restricted 
epitope from the cancer-testis antigen SSX2 for adoptive 
immunotherapy of cancer. PloS one. 2014; 9:e93321.
101. Hiasa A, Nishikawa H, Hirayama M, Kitano S, Okamoto S, 
Chono H, Yu SS, Mineno J, Tanaka Y, Minato N, Kato I 
and Shiku H. Rapid alphabeta TCR-mediated responses in 
gammadelta T cells transduced with cancer-specific TCR 
genes. Gene Ther. 2009; 16:620-628.
102. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, 
Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, 
Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller 
AD, Hessman CJ, Stewart AA, et al. Cancer regression and 
neurological toxicity following anti-MAGE-A3 TCR gene 
therapy. Journal of immunotherapy. 2013; 36:133-151.
103. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, 
Levine BL, Emery L, Litzky L, Bagg A, Carreno BM, 
Cimino PJ, Binder-Scholl GK, Smethurst DP, Gerry AB, 
Pumphrey NJ, Bennett AD, Brewer JE, et al. Cardiovascular 
toxicity and titin cross-reactivity of affinity-enhanced T 
cells in myeloma and melanoma. Blood. 2013; 122:863-
871.
104. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan 
V, Bianchi FC, Grand F, Brewer JE, Gupta M, Plesa G, 
Bossi G, Vuidepot A, Powlesland AS, Legg A, Adams KJ, 
Bennett AD, et al. Identification of a Titin-derived HLA-A1-
presented peptide as a cross-reactive target for engineered 
MAGE A3-directed T cells. Science translational medicine. 
2013; 5:197ra103.
105. Makin G and Hickman JA. Apoptosis and cancer 
chemotherapy. Cell and tissue research. 2000; 301:143-152.
106. Pennington K, Pulaski H, Pennington M and Liu JR. 
Too much of a good thing: suicide prevention promotes 
chemoresistance in ovarian carcinoma. Current cancer drug 
targets. 2010; 10:575-583.
107. Goodyear O, Agathanggelou A, Novitzky-Basso I, Siddique 
S, McSkeane T, Ryan G, Vyas P, Cavenagh J, Stankovic 
T, Moss P and Craddock C. Induction of a CD8+ T-cell 
response to the MAGE cancer testis antigen by combined 
treatment with azacitidine and sodium valproate in patients 
with acute myeloid leukemia and myelodysplasia. Blood. 
2010; 116:1908-1918.
108. Toor AA, Payne KK, Chung HM, Sabo RT, Hazlett AF, 
Kmieciak M, Sanford K, Williams DC, Clark WB, Roberts 
CH, McCarty JM and Manjili MH. Epigenetic induction of 
adaptive immune response in multiple myeloma: sequential 
azacitidine and lenalidomide generate cancer testis antigen-
specific cellular immunity. British journal of haematology. 
2012; 158:700-711.
109. Sigalotti L, Coral S, Fratta E, Lamaj E, Danielli R, Di 
Giacomo AM, Altomonte M and Maio M. Epigenetic 
modulation of solid tumors as a novel approach for cancer 
immunotherapy. Semin Oncol. 2005; 32:473-478.
110. Issa JP. Decitabine. Current opinion in oncology. 2003; 
15:446-451.
111. Yan M, Himoudi N, Basu BP, Wallace R, Poon E, Adams 
S, Hasan F, Xue SA, Wilson N, Dalgleish A, Williams 
O and Anderson J. Increased PRAME antigen-specific 
killing of malignant cell lines by low avidity CTL clones, 
following treatment with 5-Aza-2’-Deoxycytidine. Cancer 
immunology, immunotherapy : CII. 2011; 60:1243-1255.
112. Cruz CR, Gerdemann U, Leen AM, Shafer JA, Ku S, 
Tzou B, Horton TM, Sheehan A, Copeland A, Younes A, 
Rooney CM, Heslop HE and Bollard CM. Improving T-cell 
therapy for relapsed EBV-negative Hodgkin lymphoma by 
targeting upregulated MAGE-A4. Clinical cancer research 
: an official journal of the American Association for Cancer 
Research. 2011; 17:7058-7066.
Oncotarget15787www.impactjournals.com/oncotarget
113. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman 
JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, 
Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, 
Lorigan P, Vaubel JM, Linette GP, et al. Improved survival 
with ipilimumab in patients with metastatic melanoma. The 
New England journal of medicine. 2010; 363:711-723.
114. Robert C, Thomas L, Bondarenko I, O’Day S, M DJ, Garbe 
C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, 
Richards J, Maio M, Hauschild A, Miller WH, Jr., Gascon 
P, et al. Ipilimumab plus dacarbazine for previously 
untreated metastatic melanoma. The New England journal 
of medicine. 2011; 364:2517-2526.
115. Topalian SL, Sznol M, McDermott DF, Kluger HM, 
Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, 
Atkins MB, Powderly JD, Leming PD, Lipson EJ, Puzanov 
I, Smith DC, Taube JM, Wigginton JM, et al. Survival, 
durable tumor remission, and long-term safety in patients 
with advanced melanoma receiving nivolumab. Journal of 
clinical oncology : official journal of the American Society 
of Clinical Oncology. 2014; 32:1020-1030.
116. Ge Y, Xi H, Ju S and Zhang X. Blockade of PD-1/PD-L1 
immune checkpoint during DC vaccination induces potent 
protective immunity against breast cancer in hu-SCID mice. 
Cancer letters. 2013; 336:253-259.
117. Daftarian P, Song GY, Ali S, Faynsod M, Longmate J, 
Diamond DJ and Ellenhorn JD. Two distinct pathways of 
immuno-modulation improve potency of p53 immunization 
in rejecting established tumors. Cancer research. 2004; 
64:5407-5414.
118. Saha A and Chatterjee SK. Combination of CTL-associated 
antigen-4 blockade and depletion of CD25 regulatory T 
cells enhance tumour immunity of dendritic cell-based 
vaccine in a mouse model of colon cancer. Scandinavian 
journal of immunology. 2010; 71:70-82.
119. Pedersen AE, Buus S and Claesson MH. Treatment of 
transplanted CT26 tumour with dendritic cell vaccine in 
combination with blockade of vascular endothelial growth 
factor receptor 2 and CTLA-4. Cancer letters. 2006; 
235:229-238.
